Article: Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleBosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension
AuthorsMok, MY1
Tsang, PL1
Lam, YM1
Lo, Y1
Wong, WS1
Lau, CS1
Issue Date2007
PublisherSage Publications Ltd. The Journal's web site is located at http://lup.sagepub.com
CitationLupus, 2007, v. 16 n. 4, p. 279-285 [How to Cite?]
DOI: http://dx.doi.org/10.1177/0961203307076509
AbstractPulmonary arterial hypertension (PAH) in patients with systemic lupus erythematosus (SLE) is uncommon but is associated with poor survival. This study aimed to examine the long-term effects of bosentan, a dual endothelin-1 receptor antagonist, on symptomatology, haemodynamics and quality of life measures in SLE patients with symptomatic PAH. Four local patients had been followed up prospectively with pre-defined protocol during 12-months of bosentan treatment. Six minute walk distance (6MWD), NYHA functional class, Borg Dyspnoea Index (BDI) and SF-36 were measured at 0, 3, 6, 9 and 12 months. Systolic pulmonary arterial pressure (PAP) was measured by transthoracic echocardiography at zero, six and 12 months. Clinical parameters were analysed, pooling data from other SLE patients reported in the literature (n = 4). Bosentan was found to result in significant improvement in 6MWD compared to baseline [+24.8 m, +26.2 m, +54 m and +62.7 m at three (P = 0.001), six (P = 0.001), nine (P = 0.24) and 12 (P = 0.01) months respectively]. A differential effect was found with greater response in patients with lower exercise capacity. This was accompanied by decrease in NYHA functional class, BDI, transient or sustained drop in systolic PAP and mild improvement in SF-36 domains including mental health, vitality, social function and general health. Significantly deranged liver function was found in one patient. © 2007 SAGE Publications.
ISSN0961-2033
2011 Impact Factor: 2.337
2011 SCImago Journal Rankings: 0.226
DOIhttp://dx.doi.org/10.1177/0961203307076509
ISI Accession Number IDWOS:000246669200007
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorMok, MY
dc.contributor.authorTsang, PL
dc.contributor.authorLam, YM
dc.contributor.authorLo, Y
dc.contributor.authorWong, WS
dc.contributor.authorLau, CS
dc.date.accessioned2010-09-06T07:34:00Z
dc.date.available2010-09-06T07:34:00Z
dc.date.issued2007
dc.description.abstractPulmonary arterial hypertension (PAH) in patients with systemic lupus erythematosus (SLE) is uncommon but is associated with poor survival. This study aimed to examine the long-term effects of bosentan, a dual endothelin-1 receptor antagonist, on symptomatology, haemodynamics and quality of life measures in SLE patients with symptomatic PAH. Four local patients had been followed up prospectively with pre-defined protocol during 12-months of bosentan treatment. Six minute walk distance (6MWD), NYHA functional class, Borg Dyspnoea Index (BDI) and SF-36 were measured at 0, 3, 6, 9 and 12 months. Systolic pulmonary arterial pressure (PAP) was measured by transthoracic echocardiography at zero, six and 12 months. Clinical parameters were analysed, pooling data from other SLE patients reported in the literature (n = 4). Bosentan was found to result in significant improvement in 6MWD compared to baseline [+24.8 m, +26.2 m, +54 m and +62.7 m at three (P = 0.001), six (P = 0.001), nine (P = 0.24) and 12 (P = 0.01) months respectively]. A differential effect was found with greater response in patients with lower exercise capacity. This was accompanied by decrease in NYHA functional class, BDI, transient or sustained drop in systolic PAP and mild improvement in SF-36 domains including mental health, vitality, social function and general health. Significantly deranged liver function was found in one patient. © 2007 SAGE Publications.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationLupus, 2007, v. 16 n. 4, p. 279-285 [How to Cite?]
DOI: http://dx.doi.org/10.1177/0961203307076509
dc.identifier.doihttp://dx.doi.org/10.1177/0961203307076509
dc.identifier.epage285
dc.identifier.hkuros134353
dc.identifier.isiWOS:000246669200007
dc.identifier.issn0961-2033
2011 Impact Factor: 2.337
2011 SCImago Journal Rankings: 0.226
dc.identifier.issue4
dc.identifier.openurl
dc.identifier.pmid17439935
dc.identifier.scopuseid_2-s2.0-34249015268
dc.identifier.spage279
dc.identifier.urihttp://hdl.handle.net/10722/77631
dc.identifier.volume16
dc.languageeng
dc.publisherSage Publications Ltd. The Journal's web site is located at http://lup.sagepub.com
dc.publisher.placeUnited Kingdom
dc.relation.ispartofLupus
dc.relation.referencesReferences in Scopus
dc.rightsLupus. Copyright © Sage Publications Ltd.
dc.subject.meshAdult
dc.subject.meshAntihypertensive Agents - therapeutic use
dc.subject.meshBlood Pressure - drug effects
dc.subject.meshExercise Tolerance
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshHypertension, Pulmonary - complications - drug therapy
dc.subject.meshLupus Erythematosus, Systemic - complications
dc.subject.meshMiddle Aged
dc.subject.meshQuality of Life
dc.subject.meshSeverity of Illness Index
dc.subject.meshSulfonamides - therapeutic use
dc.subject.meshTreatment Outcome
dc.titleBosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension
dc.typeArticle
Author Affiliations
  1. Queen Mary Hospital Hong Kong